Viewing nowCombinationGenodron Plus D Tablets
Sodium Alendronate Trihydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.

MFDS item code 201404026 · Approved 2014.08.28 · Insurance code 650303240
Treatment of osteoporosis in postmenopausal women and men
This medication is used to treat osteoporosis that can occur in both postmenopausal women and men.
Take 1 tablet (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with a sufficient amount of water, at least 30 minutes before consuming food, beverages, or other medicines (see “General Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The appropriate duration of treatment has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on clinical data from 4 years. The need for continued treatment should be reviewed regularly for all patients receiving bisphosphonates. In patients at low risk of fracture, discontinuation should be considered after 3~5 years of treatment. The risk of fracture should be reassessed regularly in patients who discontinue treatment. Other beverages or food, including mineral water and barley tea, and medicines may decrease the absorption of alendronate (see “Interactions”). Consuming food within 30 minutes after taking this medicine or at the same time may decrease the absorption of alendronate and reduce its effect. This medicine should be taken immediately after getting up in the morning with a sufficient amount of water (170∼230 mL) to facilitate rapid passage of the medicine to the stomach and reduce the possibility of esophageal irritation. After taking it, do not lie down for at least 30 minutes and until after the first food intake. Do not take this medicine at bedtime or before getting up. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “General Precautions”). Patients with inadequate calcium and vitamin D intake from food should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to Be Provided to Patients (4)). Patients at increased risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic illness) may require additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. This medicine, taken once weekly, provides a week's supply of 400 IU or 800 IU of vitamin D per day. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the next morning, resume taking it on the originally scheduled day, and then continue taking it regularly once weekly. Do not take 2 tablets on the same day. Administration to older adults (65 years or older): No dose adjustment is necessary. Administration to patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min). However, administration of this medicine is not recommended in patients with severe renal impairment (creatinine clearance less than 35 mL/min) because there is insufficient clinical experience.
Children and adolescents (under 18 years): Safety and efficacy in children and adolescents have not been established.
This medication can irritate the mucosa of the upper gastrointestinal tract, which may lead to symptoms such as esophagitis, esophageal ulcers, and esophageal erosions. When taking this medication, it should be taken with a sufficient amount of water, and you should not lie down for at least 30 minutes after taking it. If symptoms such as dysphagia, odynophagia, pain behind the sternum, or heartburn occur, stop taking the medication immediately and consult a doctor. Patients with esophageal strictures or achalasia that delay esophageal emptying, patients who cannot remain upright for more than 30 minutes, patients allergic to any component of the medication, patients with hypocalcemia, and patients with certain genetic disorders should not take this medication. Adverse gastrointestinal reactions may occur while taking this medication, including abdominal pain, nausea, indigestion, constipation, diarrhea, gastric acid reflux, esophagitis, musculoskeletal pain, headache, dizziness, and alteration of taste, have been reported. Particularly in postmenopausal women and men receiving osteoporosis treatment, gastrointestinal symptoms and musculoskeletal pain may occur, so caution is advised. When taking this medication, it should be done in the morning, with sufficient water before consuming other foods, beverages, or medications, and you should remain upright and avoid lying down for at least 30 minutes post-administration. If calcium intake is insufficient, calcium supplements should be taken, and patients at high risk of vitamin D deficiency should also require vitamin D supplementation. This medication may be absorbed less effectively when taken with calcium supplements or antacids, so a gap of at least 30 minutes between doses should be maintained, and gastrointestinal adverse reactions may increase when used in combination with aspirin or non-steroidal anti-inflammatory drugs. During pregnancy or breastfeeding, it should be administered cautiously after thorough consultation with a physician, and it is not recommended for children or patients with severely impaired renal function. In cases of overdose, hypocalcemia or gastrointestinal adverse reactions may occur, so immediate consultation with healthcare professionals is necessary, and do not induce vomiting but keep the patient in an upright position. This medication should be kept out of reach of children and should not be transferred to other containers for safety.
Esophagitis, esophageal ulcer, esophageal erosion, esophageal obstruction, perforation, bleeding, dysphagia, odynophagia, retrosternal pain, heartburn, abdominal pain, nausea, indigestion, constipation, diarrhea, flatulence, acid reflux, vomiting, abdominal bloating, gastritis, musculoskeletal (bone, muscle, or joint) pain, muscle cramps, headache, dizziness, taste disorders, rash, erythema, anastomotic ulcers, urticaria, angioedema, myalgia, malaise, asthenia, fever, symptoms of hypocalcemia, peripheral edema, oral-pharyngeal ulcers, gastric ulcer, duodenal ulcer, localized jaw bone necrosis, joint swelling, low-energy fractures of the femoral neck and other bones, itching, hair loss, Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, scleritis, episcleritis, cholesteatoma of the external auditory canal, nasopharyngitis
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a sealed container. It is also advisable to keep it away from direct sunlight and at room temperature between 1 and 30 degrees Celsius.
White to grayish-white rectangular tablet
4 tablets (4 tablets x 1 PTP)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSodium Alendronate Trihydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
CombinationSodium Alendronate Trihydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationSodium Alendronate Trihydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSodium Alendronate Trihydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.
CombinationSodium Alendronate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
Sodium Alendronate Hydrate · Cholecalciferol Concentrate Powder
Prescription medication · Combination
Youngjin Pharmaceutical Co., Ltd.
CombinationSodium Alendronate Trihydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
CombinationSodium Alendronate Trihydrate 91.37mg · Cholecalciferol Concentrate Powder 53.33mg
Tablet · Prescription medication · Combination
Samik Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.